EFFECTS OF IPSAPIRONE AND CANNABIDIOL ON HUMAN EXPERIMENTAL ANXIETY

被引:260
作者
ZUARDI, AW
COSME, RA
GRAEFF, FG
GUIMARAES, FS
机构
[1] FFCLRP, FAC MED, DEPT NEUROPSYCHIAT, BR-14049 RIBEIRAO PRETO, SP, BRAZIL
[2] FFCLRP, FAC MED, DEPT PHARMACOL, BR-14049 RIBEIRAO PRETO, SP, BRAZIL
[3] FFCLRP, PSYCHOBIOL LAB, BR-14049 RIBEIRAO PRETO, SP, BRAZIL
关键词
CANNABIDIOL; DIAZEPAM; IPSAPIRONE; ANXIETY; PUBLIC SPEAKING;
D O I
10.1177/026988119300700112
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogae Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
引用
收藏
页码:82 / 88
页数:7
相关论文
共 44 条
[1]   INTERACTIONS OF DELTA-1-TETRAHYDROCANNABINOL WITH CANNABINOL AND CANNABIDIOL FOLLOWING ORAL-ADMINISTRATION IN MAN - ASSAY OF CANNABINOL AND CANNABIDIOL BY MASS FRAGMENTOGRAPHY [J].
AGURELL, S ;
CARLSSON, S ;
LINDGREN, JE ;
OHLSSON, A ;
GILLESPIE, H ;
HOLLISTER, L .
EXPERIENTIA, 1981, 37 (10) :1090-1092
[2]  
BENEKE M, 1988, PSYCHOPHARMACOLOGY S, V96, P353
[3]  
Biaggio A. M., 1976, CROSS CULTURAL RES A, P29
[4]   USE OF ANALOG SCALES IN RATING SUBJECTIVE FEELINGS [J].
BOND, A ;
LADER, M .
BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1974, 47 (SEP) :211-218
[5]   STRUCTURE ACTIVITY RELATIONSHIP OF 4 TETRAHYDROCANNABINOLS AND PHARMACOLOGICAL ACTIVITY OF 5 SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA [J].
CARLINI, EA ;
SANTOS, M ;
CLAUSSEN, U ;
BIENIEK, D ;
KORTE, F .
PSYCHOPHARMACOLOGIA, 1970, 18 (01) :82-&
[6]   CONTROLLED CLINICAL-TRIAL OF CANNABIDIOL IN HUNTINGTONS-DISEASE [J].
CONSROE, P ;
LAGUNA, J ;
ALLENDER, J ;
SNIDER, S ;
STERN, L ;
SANDYK, R ;
KENNEDY, K ;
SCHRAM, K .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (03) :701-708
[7]  
CRITCHLEY M A E, 1987, British Journal of Pharmacology, V92, p660P
[8]  
CSANALOSI I, 1987, J CLIN PSYCHOPHARM, V7, P31
[9]   CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY-VOLUNTEERS AND EPILEPTIC PATIENTS [J].
CUNHA, JM ;
CARLINI, EA ;
PEREIRA, AE ;
RAMOS, OL ;
PIMENTEL, C ;
GAGLIARDI, R ;
SANVITO, WL ;
LANDER, N ;
MECHOULAM, R .
PHARMACOLOGY, 1980, 21 (03) :175-185
[10]  
DALTON WS, 1976, CLIN PHARMACOL THER, V19, P300